-+ 0.00%
-+ 0.00%
-+ 0.00%

CRINETICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1/2 TRIAL EVALUATING CRN09682 FOR THE TREATMENT OF NEUROENDOCRINE TUMORS AND OTHER SOMATOSTATIN RECEPTOR 2-EXPRESSING TUMORS

路透·12/03/2025 13:05:32

登录查看新闻详情